Mark's expertise lies at the intersection of technology and neuroscience with extensive experience in software development and AI focused on image management and analysis solutions. Mark graduated from Oxford University with a Masters in Engineering, and holds a PhD in Information Engineering also from Oxford University, where he worked in the Wolfson Medical Visions Lab focussed on computer vision, artificial intelligence and software development. Since joining IXICO in 2008, Mark has held various technology and development roles, playing a pivotal part in the development and evolution of the company's AI-driven platform, TrialTracker™. He leads technology strategy and initiatives to accelerate the scalability of the IXICO’s Platform.

As CBO, James is responsible for amplifying the visibility of IXICO and overseeing marketing, investor relations and corporate development, driving partnership and collaboration opportunities. He has previously served at a senior executive management level with a number of national and international biopharma organizations including BenevolentAI, Sensyne Health plc and e-therapeutics plc as well as operating as a non-executive director and board advisor to a number of biotech start-ups in the genetics and cancer diagnostics space.

Hannah is an experienced HR leader with over 14 years’ experience specialising in the charity and health sectors. Since joining IXICO in 2019, Hannah has led the HR function ensuring the people strategy is fully aligned with company’s broader corporate objectives to enhance performance and talent management, promote employee engagement and foster a strong organisational culture. Before joining IXICO, Hannah held HR business partner positions at a number of organisations including the London Women’s Clinic and Macmillan Cancer Support.

Bram has over 20 years of leadership in BioPharma and precision medicine. He held C-level roles at Eagle Genomics and SOPHiA Genetics, enhancing platform innovation and US presence. As VP at Foundation Medicine, he expanded its global precision medicine platform. As CEO of Prometheus Laboratories, he integrated it into Nestle Health Science and served as Head of Brain Health. Earlier, he held senior roles at UCB Pharma and Eli Lilly, launching CNS medicines globally. Bram’s board experience includes Mantis Photonics and Cerecin Inc. He is passionate about patient care and values diverse teams. His strategic vision and leadership have consistently driven growth and shareholder value.

Appointment to Board:
August 2024

Having qualified as a Solicitor in 2000, Anna-Maria has over 20 years of experience of working as an in-house commercial lawyer across a number of sectors for organisations such as the London Stock Exchange subsidiary FTSE Russel and the publishing group De Agostini. Anna-Maria joined IXICO in 2020. In her role as General Counsel, Anna-Maria manages all legal, compliance and contractual matters for the Company.

Grant has worked in the life sciences sector for over 20 years. In his executive director role, Grant leads the Company's Finance, Legal and IT functions. Grant joined IXICO from UK Biobank, an international health research data resource, where he had been Finance Director since 2014. Previous to this, he qualified as a Chartered Accountant at PwC and was SVP Finance at Evotec, the early stage drug discovery CRO. Grant is a member of the Share Transaction Committee and also acts as Secretary to the Board and its subcommittees.

Appointment to Board:
August 2019

Terry leads the global commercial strategy, driving revenue growth and expanding partnerships with leading biopharmaceutical companies focused on neuroscience. With over two decades of experience in life sciences and health technology, Terry has a proven track record of building high-performance commercial teams and delivering sustained growth across early-stage ventures, PE-backed companies, and publicly traded organizations. He has formerly served in senior commercial positions at HealhTech Connex Inc, Taconic Biosciences, Cogstate and BIO IVT.

Robin has over 15 years of experience in the development of innovative analytics solutions in healthcare with a focus on imaging technology. Prior to IXICO, Robin held different roles at Philips in the Research and Diagnostic X-Ray divisions. Robin holds a PhD in medical imaging and computer science from Imperial College London, focused on early detection of Alzheimer's disease. He is the co-author of more than 100 publications and holds multiple patents in the field of medical imaging and AI data analytics.

Mark is Chief Executive Officer of CHEMAI Ltd and is an advisor to Angelini Ventures. He is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. 

Appointment to Board:
September 2016

Bram has over 20 years of leadership in BioPharma and precision medicine. He held C-level roles at Eagle Genomics and SOPHiA Genetics, enhancing platform innovation and US presence. As VP at Foundation Medicine, he expanded its global precision medicine platform. As CEO of Prometheus Laboratories, he integrated it into Nestle Health Science and served as Head of Brain Health. Earlier, he held senior roles at UCB Pharma and Eli Lilly, launching CNS medicines globally. Bram’s board experience includes Mantis Photonics and Cerecin Inc. He is passionate about patient care and values diverse teams. His strategic vision and leadership have consistently driven growth and shareholder value.

Appointment to Board:
August 2024

Grant has worked in the life sciences sector for over 20 years. In his executive director role, Grant leads the Company's Finance, Legal and IT functions. Grant joined IXICO from UK Biobank, an international health research data resource, where he had been Finance Director since 2014. Previous to this, he qualified as a Chartered Accountant at PwC and was SVP Finance at Evotec, the early stage drug discovery CRO. Grant is a member of the Share Transaction Committee and also acts as Secretary to the Board and its subcommittees.

Appointment to Board:
August 2019

Dipti is an experienced non-executive director.  She currently sits on the Board of Lineage Cell Therapeutics, a US based biotechnology company, having previously sat on the Boards of companies in both the private and public sector.  Before this, Dipti spent over 20 years of her executive career at IQVIA occupying senior positions in compliance, drug safety and medical affairs.  Dipti is medically trained and is a Fellow of the Faculty of Pharmaceutical Medicine.  Dipti is Chair of the Remuneration and Share Transaction Committees and a member of the Audit Committee.

Appointment to Board:
October 2023